alpha-synuclein

Latest

alpha-synuclein

Featured Neurology Neuroscience Open Neuroscience Articles

·April 20, 2020·4 min read

Further evidence autoimmunity plays a role in Parkinson’s disease

T cells that react to alpha-synuclein are most abundant in the early stages of Parkinson's disease but tend to disappear as the disease progresses. Signs of autoimmunity can appear in Parkinson's patients up to ten years before a diagnosis of the neurodegenerative disease. The detection of T cell response could be an early biomarker for Parkinson's, long before the physical symptoms begin to manifest.

Featured Neurology Neuroscience

·March 13, 2020·5 min read

‘Natural killer’ cells could halt Parkinson’s progression

Natural killer cells may play a critical role in regulating and restraining neuroinflammation and protein clumping associated with Parkinson's disease.

Featured Neurology Neuroscience

·March 11, 2020·5 min read

New target for Parkinson’s therapies identified

Two regions outside of the non-amyloid-beta-component play a critical role in controlling amyloid formation of alpha-synuclein.

Featured Neurology Neuroscience

·February 18, 2020·5 min read

Parkinson’s biomarker may originate in gut

Using mouse models, researchers seeded alpha-synuclein aggregates in gut neurons and discovered the clumps can travel to neurons in the brain.

Featured Neurology Neuroscience Open Neuroscience Articles

·February 16, 2020·4 min read

Cough syrup drug being trialed as Parkinson’s treatment

Ambroxol, a medication approved to treat coughs, may slow the progression of Parkinson's disease. The medication is able to effectively cross the blood-brain barrier and increases levels of GCase in patients' brains. Ambroxol also appears to reduce Parkinson's-related alpha-synuclein levels.

Featured Genetics Neurology Neuroscience

·January 27, 2020·5 min read

Parkinson’s disease may start before birth

10% of patients diagnosed with Parkinson's disease are between the ages of 21 and 50. For those with young-onset Parkinson's disease, researchers report the foundations for the disease may have been apparent before they were born. The study also points to a drug, currently approved to treat precancerous skin growths, that has the potential to reduce elevated levels of alpha-synuclein.

Featured Genetics Neurology Neuroscience Open Neuroscience Articles

·January 17, 2020·3 min read

New insights into a Parkinson’s disease protein

Alpha synuclein's non-amyloidal component (NAC) aids the protein's movement through axons. When the NAC region is removed, alpha-synuclein did not move within axons.

Featured Neurology Neuroscience Open Neuroscience Articles

·January 14, 2020·3 min read

Probiotic could guard against Parkinson’s

Building on previous research that links gut bacteria to the development of Parkinson's disease, researchers identified a probiotic which prevents the formation of alpha-synuclein.

Featured Neurology Neuroscience Open Neuroscience Articles

·November 14, 2019·4 min read

Targeting alpha-synuclein in the gut may slow down Parkinson’s disease

Scientists are conducting experiments to see if targeting the enteric nervous system with a compound can inhibit the aggregation of alpha-synuclein and slow the progression of Parkinson's disease.

This shows the outline of two bodies. One has the head highlighted red, the other has the gut highlighted red

Featured Neurology Neuroscience Open Neuroscience Articles

·November 7, 2019·4 min read

Where does Parkinson’s disease start? In the brain or gut? Or both?

Lewy body disorders, including Parkinson's disease and Lewy body dementia, comprise of two distinct subtypes. One subtype originates in the peripheral nervous system (PNS) of the gut and spreads to the brain. The other originates in the brain, or enters the brain via the olfactory system, before spreading to the brainstem and PNS.

Featured Neurology Neuroscience

·October 3, 2019·5 min read

Parkinson’s disease is also present in the blood

Parkinson's disease involves monocytic alterations in the blood. The cells have reduced viability and are unresponsive to specific stimuli, which could have relevant consequences for the progression of Parkinson's. Immune modulation medications may be a new treatment option to inhibit neurodegeneration associated with PD.

Featured Neurology Neuroscience Open Neuroscience Articles

·September 3, 2019·4 min read

Parkinson’s disease may originate in the intestines

Two months after injecting alpha-synuclein into the intestines of rats, researchers discovered the proteins had traveled to the brain via peripheral nerves. Four months later, the pathology was greater. Additionally, the protein had traveled to the heart. The study supports the hypothesis that Parkinson's disease may begin in the intestinal system before migrating to the brain.

1 2 3 4 … 10

Username
Password

	Remember Me Lost your password?